Results 261 to 270 of about 164,269 (359)

274 Hepatic steatosis is a risk factor for the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma

open access: bronze, 2006
Sanae Saito   +4 more
openalex   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hepatitis C virus (HCV) infection is an infectious disease carrying a high risk of metabolic disorders. Chronic HCV (CHC) patients can possess extrahepatic manifestations such as diabetes, steatotic liver disease (SLD), and other metabolic alterations.
Chung‐Feng Huang   +3 more
wiley   +1 more source

T1614 Adipocyte Apoptosis: A Link Between Obesity, Insulin Resistance and Hepatic Steatosis

open access: bronze, 2009
Naim Alkhouri   +7 more
openalex   +1 more source

Liver Steatosis in Induced Hepatocytes From Carriers of Spinal Muscular Atrophy

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Although classically characterized as a motor neuron disease, spinal muscular atrophy (SMA) is increasingly recognized as a multisystem disorder. We previously showed hepatocyte‐intrinsic steatosis in SMA, raising the question of whether SMA carriers, who are typically asymptomatic, may also exhibit subclinical hepatic ...
Lingyu Sun   +15 more
wiley   +1 more source

Expanding the Differential Diagnosis of Ultrasonographic Flexor Digitorum Profundus–Flexor Carpi Ulnaris Dissociation of Echogenicity: Muscular Dystrophies

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Dissociation of echogenicity of the flexor digitorum profundus (FDP) and flexor carpi ulnaris (FCU) on neuromuscular ultrasound has been reported to be a useful sign to differentiate inclusion body myositis (IBM) from more common disease mimics, but it is not clear that this finding is pathognomonic of IBM. Our study aimed to
Anson W. Wilks, Nizar Chahin
wiley   +1 more source

Nanoformulated Diacerein Alleviates Hyperlipidemia via Gut Microbiota Modulation In Vivo

open access: yesNano Select, EarlyView.
A nanoformulation of diacerein (Nano‐DIA) was fabricated with carboxymethyl cellulose, achieving enhanced solubility and rapid dissolution for alternative anti‐hyperlipidemia therapeutics. Mechanistic studies revealed its in vivo lipid‐lowering efficacy is through metabolite‐mediated and microbiota‐dependent manner, highlighting its dual action on host
Zheng Peng   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy